I am a molecular biologist focused on hereditary cancer genetics in the Pakistani population. My research explores germline mutations and epigenetic alterations in breast, ovarian, colorectal, pancreatic, and brain cancers. I have made significant contributions to understanding early-onset and familial cancers in South Asia, uncovering novel pathogenic variants and mutation spectra in key cancer susceptibility genes, including BRCA1/2, PALB2, RAD51C/D, FANCM, MLH1, MSH2, and MSH6. My work also addresses the role of promoter methylation in cancer predisposition. I collaborate with national and international teams to improve genetic testing, counseling, and personalized risk assessment, particularly in resource-limited settings. I also investigate host genetic factors, such as ACE2 variants in SARS-CoV-2 infection, to broaden the scope of precision medicine. Research Interests: Hereditary Cancer Genetics: Identifying germline mutations in high-penetrance cancer susceptibility genes in Pakistani cohorts (e.g., BRCA1/2, PALB2, RAD51C/D, FANCM). Epigenetics: Studying promoter methylation (e.g., BRCA1, MLH1) to understand non-mutational gene inactivation in hereditary cancers. Population-Specific Mutation Spectrum: Defining founder mutations for genetic screening in Pakistan. Molecular Pathogenesis: Investigating genetic and epigenetic factors in early-onset and familial cancers. Host Genetics in Infectious Diseases: Exploring genetic determinants in viral infections.